Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HER2-CAR autologous CMV-specific cytotoxic T lymphocytes

Autologous human cytomegalovirus (CMV)-specific human cytotoxic T lymphocytes (CTLs) transduced with a retroviral vector encoding a human anti-HER2 (epidermal growth factor receptor 2) chimeric T cell receptor (CAR) gene with potential immunostimulatory and antineoplastic activities. Autologous CTLs from a patient with HER2- and CMV-positive glioblastoma multiforme (GBM) are genetically modified to express CAR gene specific for HER2 on their cell surfaces. After expansion in culture and reintroduction into the patient, the anti-HER2-CAR autologous CMV-specific CTLs bind to HER2 antigen on tumor cell surfaces; subsequently, HER2-positive tumor cells and stem cells may be lysed. HER2 (ErbB2), a receptor tyrosine kinase (RTK) overexpressed by a variety of cancer cell types, plays key roles in tumor cell proliferation and tumor angiogenesis. CMV is present in the majority of GBM tumors.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search